This randomized clinical trial evaluates the efficacy and safety of fingolimod, 0.5 mg, and fingolimod, 0.25 mg, compared with glatiramer acetate, 20 mg, and examines whether these fingolimod doses show superior efficacy to glatiramer acetate for the treatment of adult patients with relapsing-remitting multiple sclerosis.
from journals https://ift.tt/2QlnSie
from journals https://ift.tt/2QlnSie
Comments
Post a Comment